Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Medical University of South Carolina: Clinical Trials & FDA Approval Profile

Medical University of South Carolina (Global / Institutional) sponsors 74 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 33 active protocols (25 recruiting now), 31 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)13.5%
Median Closed Enrollment vs National (145 pts)47 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Medical University of South Carolina
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)74
Active Pipeline (Recruiting Now)33 (25)
Completed vs Stopped Early31 / 10 (13.5%)
Median Closed Actual Enrollment47 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Medical University of South Carolina
Hospital Research SiteLocationShared Protocols
Medical University of South CarolinaCharleston, SC52
Emory Winship Cancer InstituteAtlanta, GA3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Medical University of South Carolina
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT02633163Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)Phase IICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Medical University of South Carolina Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI